Blog

Oct 21, 2024

NI could face medicine shortages, warns pharmaceutical body - BBC News

Image source, PA A pharmaceutical body has warned of potential shortages of some medicines in Northern Ireland unless there is a delay to the implementation of the Windsor Framework. The framework is

Image source, PA

A pharmaceutical body has warned of potential shortages of some medicines in Northern Ireland unless there is a delay to the implementation of the Windsor Framework.

The framework is the post-Brexit deal between the EU and UK which governs trade between Great Britain and Northern Ireland.

A new requirement for the labelling of medicines is due to be implemented from 1 January 2025.

But the British Generic Manufacturers Association (BGMA) has said that not all suppliers will be ready.

It is understood the UK government is confident that transitional measures will avoid disruption and it is not planning to ask the EU for an extension.

The BGMA’s concerns were first reported by the Financial Times.

Mark Samuels, chief executive of the BGMA, said the industry "fully supports" the framework and the intent behind the labelling change.

However he added that the change was more complex and time consuming than anticipated.

"We are facing an absurd situation where patients in Northern Ireland will go without access to millions of packs of medicines due to a technical and artificial deadline when shortages are already at a record high. We need to serve the best interests of patients, not bureaucracy," he said.

The supply of medicines from GB to NI has been one of the most complex post-Brexit issues and the original agreement reached in 2019 has been amended several times.

The Windsor Framework included an agreement that manufacturers could produce a single medicines pack for the whole of the UK, including Northern Ireland.

That means the relevant medicines must be labelled ‘UK only.’

That may sound relatively trivial but manufacturers had warned that an earlier plan to require Northern Ireland-specific labelling was commercially unviable and would have led to some products being withdrawn.

The BGMA said the operational work in factories to get the new ‘UK only’ packaging ready would be "mostly completed for 1 January, but there will be an unavoidable spill over in the first half of 2025".

Mr Samuel’s said they were urging the government and the European Commission not to enforce the new rule from 1 January, "as the consequences could be severe for patients".

Other aspects of the Windsor Framework have already been delayed.